A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Conditions
- Prostate Cancer
- Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer Metastatic to Bone
Interventions
- PROCEDURE: Blood Tests
- PROCEDURE: CT scan
- PROCEDURE: FACBC PET/MRI in a subset of participants
- DRUG: Radium-223 dichloride
- PROCEDURE: bone scan
Sponsor
Massachusetts General Hospital
Collaborators